JP2008514607A5 - - Google Patents

Download PDF

Info

Publication number
JP2008514607A5
JP2008514607A5 JP2007533565A JP2007533565A JP2008514607A5 JP 2008514607 A5 JP2008514607 A5 JP 2008514607A5 JP 2007533565 A JP2007533565 A JP 2007533565A JP 2007533565 A JP2007533565 A JP 2007533565A JP 2008514607 A5 JP2008514607 A5 JP 2008514607A5
Authority
JP
Japan
Prior art keywords
surfactant
substance
soluble active
optionally
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007533565A
Other languages
English (en)
Japanese (ja)
Other versions
JP4977611B2 (ja
JP2008514607A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/033324 external-priority patent/WO2006036614A2/en
Publication of JP2008514607A publication Critical patent/JP2008514607A/ja
Publication of JP2008514607A5 publication Critical patent/JP2008514607A5/ja
Application granted granted Critical
Publication of JP4977611B2 publication Critical patent/JP4977611B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007533565A 2004-09-24 2005-09-16 新規な種類の界面活性剤様物質 Expired - Fee Related JP4977611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61271604P 2004-09-24 2004-09-24
US60/612,716 2004-09-24
PCT/US2005/033324 WO2006036614A2 (en) 2004-09-24 2005-09-16 A new class of surfactant-like materials comprising vitamin e tpgs and a water soluble polymer

Publications (3)

Publication Number Publication Date
JP2008514607A JP2008514607A (ja) 2008-05-08
JP2008514607A5 true JP2008514607A5 (enExample) 2008-11-06
JP4977611B2 JP4977611B2 (ja) 2012-07-18

Family

ID=36119387

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533565A Expired - Fee Related JP4977611B2 (ja) 2004-09-24 2005-09-16 新規な種類の界面活性剤様物質

Country Status (6)

Country Link
US (1) US20060068007A1 (enExample)
EP (1) EP1799194B1 (enExample)
JP (1) JP4977611B2 (enExample)
AT (1) ATE533473T1 (enExample)
CA (1) CA2578356C (enExample)
WO (1) WO2006036614A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090094815A (ko) * 2006-11-09 2009-09-08 애보트 게엠베하 운트 콤파니 카게 티로신 키나아제 억제제의 경구 투여를 위한 약제 투여형
US20100016449A1 (en) * 2006-12-21 2010-01-21 Boehringer Ingelheim International Gmbh Formulations with Improved Bioavailability
WO2008093358A2 (en) * 2007-01-29 2008-08-07 Sun Pharmaceutical Industries Limited Aqueous topical solution containing olopatadine
JP5668476B2 (ja) 2007-10-08 2015-02-12 オーリニア・ファーマシューティカルズ・インコーポレイテッドAurinia Pharmaceuticals Inc. カルシニューリン阻害剤またはmTOR阻害剤を含む眼科用組成物
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
MX338355B (es) 2009-06-09 2016-04-13 Aurinia Pharmaceuticals Inc Sistemas de suministro de farmaco topico para uso oftalmico.
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
CN103118681B (zh) * 2010-03-10 2015-02-18 艾伯维巴哈马有限公司 固体组合物
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状c型肝炎セリンプロテアーゼ阻害剤
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
EP2900219B1 (en) * 2012-09-27 2016-07-06 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9789063B2 (en) * 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN108659214A (zh) * 2018-05-21 2018-10-16 上海联陆实业股份有限公司 无溶剂合成水溶性维生素e聚乙二醇琥珀酸酯的制备方法
EP4282475A3 (en) * 2019-12-20 2024-02-28 Intervet International B.V. A pyrazole pharmaceutical composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
US5696101A (en) 1996-04-16 1997-12-09 Eastman Chemical Company Oxidized cellulose and vitamin E blend for topical hemostatic applications
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
US6280770B1 (en) 1998-08-13 2001-08-28 Cima Labs Inc. Microemulsions as solid dosage forms for oral administration
US6331581B1 (en) * 1998-12-24 2001-12-18 Kansai Paint Co., Ltd. Method for color matching of powder coating composition and process for the preparation thereof
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6416793B1 (en) * 2000-07-11 2002-07-09 Bioresponse, L.L.C. Formulations and use of controlled-release indole alkaloids
DE10046541A1 (de) * 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
ES2259079T3 (es) 2001-01-19 2006-09-16 Smithkline Beecham Corporation Inhibidores de la actividad cinasa del receptor tie2 para tratar enfermedades angiogenicas.
US7172770B2 (en) 2001-02-19 2007-02-06 Board Of Regents, The University Of Texas System Mesoporous compositions for use in drug delivery
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
JP2003252750A (ja) * 2002-02-26 2003-09-10 ▲寛▼治 ▲高▼田 水溶性の難・低吸収性薬物のバイオアベイラビリティ改善技術

Similar Documents

Publication Publication Date Title
JP2008514607A5 (enExample)
ES2613608T3 (es) Composiciones sólidas
ES2768349T3 (es) Preparación farmacéutica que comprende un derivado de fenilalanina
ES2731881T3 (es) Composiciones que comprenden compuestos activos lipófilos y método para su preparación
EP3076951B1 (en) Process for the production of drug formulations for oral administration
US20060068010A1 (en) Method for improving the bioavailability of orally delivered therapeutics
RU2446800C2 (ru) Препаративные формы с контролируемым высвобождением
Sruti et al. Improvement in the dissolution rate and tableting properties of cefuroxime axetil by melt-granulated dispersion and surface adsorption
UA105434C2 (uk) Тверда композиція та спосіб лікування вірусу гепатиту с
Kumar et al. Pharmaceutical solid dispersion technology: a strategy to improve dissolution of poorly water-soluble drugs
TW202112376A (zh) 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
Afzal et al. Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals
CN102149715A (zh) 肝适能的稳定化固态分散物及其制备方法
CN102813656A (zh) 5-甲基四氢叶酸或其盐的稳定药物组合物
US9469673B2 (en) Crystaline forms of HCV inhibitor
CN107427495A (zh) 包含雷迪帕韦和索非布韦的药物组合物
JP2010509400A (ja) 経口処方組成物
EP2240174A1 (en) Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide
US20160106849A1 (en) Formulations of phenyl uracil compounds
WO2020003196A1 (en) Pharmaceutical composition of axitinib
ES2301401B1 (es) Composicion farmaceutica solida estabilizada de candesartan cilexetilo.
RU2014124118A (ru) Фармацевтические препараты, включающие аторвастатин и глимепирид
US20150175612A1 (en) Crystal forms
ES2317174T3 (es) Agentes tensioactivos en forma de polvo utilizables en comprimidos o capsulas; procedimiento de preparacion y composiciones que los contienen.
Bhatane et al. Applications of mesoporous silica particles in amorphous solid dispersion